JAK1, Janus kinase 1, 3716

N. diseases: 239; N. variants: 41
Disease: Adult Lymphoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1332206
Disease: Adult Lymphoma
Adult Lymphoma 		0.010 Biomarker disease BEFREE Furthermore, whether an increased risk of lymphoma development is limited to patients who receive the JAK inhibitor ruxolitinib, is a more general phenomenon that occurs following JAK1/2 inhibition, or is associated with preferential JAK1 or JAK2 targeting is discussed.This article is protected by copyright.All rights reserved. 31833567 2019